Martinelli's recalls over 170,000 bottles of apple juice due to potentially toxic substances
'In 2024, the Food & Drug Administration (FDA) routine testing indicated that one lot of 10-ounce Martinelli's Apple Juice glass bottles (in 4-packs only) produced in December 2023 may contain elevated levels of Patulin, a naturally occurring substance produced by molds that can grow in apples,' Martinelli's said in a statement obtained by NBC News.
The FDA classified the recall as a Class II, which is described as 'a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.'
The recalled apple juice was distributed in almost 30 states. It has a 'best by' date of Dec. 5, 2026 and UPC number 0 41244 04102 2.
Martinelli's said it has worked with retailers that received the recalled product. The retailers 'have removed anything that still remained in inventory. No other production dates or Martinelli's products are affected by this recall.'
'At S. Martinelli & Company, we hold ourselves to the highest standards of excellence, and the health and safety of our customers remains our greatest priority,' the statement concluded.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Newsweek
25 minutes ago
- Newsweek
Cheese Recall as 'Serious' Contamination Warning Issued
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. An Ohio-based company has issued a voluntary recall for various cheese products due to potential contamination with Listeria monocytogenes, the U.S. Food and Drug Administration (FDA) said. Middlefield Original Cheese Co-Op announced the recall for various lots of five products on August 18 after contamination was found during its own testing. Newsweek reached out to Middlefield Original Cheese Co-op for comment by phone outside of regular working hours. Why It Matters The FDA warned that Listeria "can cause serious and sometimes fatal infections in young children, frail or elderly people, and others with weakened immune systems." Listeria infection, or listeriosis, may lead to a range of symptoms in infected individuals. For those experiencing less severe infections, symptoms may include fever, muscle aches, nausea, vomiting and diarrhea, which often last between one and three days, the FDA said. For more severe and potentially life-threatening infections, symptoms may include headaches, stiff neck, confusion, loss of balance and convulsions. Severe infections can also lead to miscarriages and stillbirths in pregnant women. Stock image of a chef displaying cheese cubes. Stock image of a chef displaying cheese cubes. Sebastian Gollnow/picture-alliance/dpa/AP Images What To Know The products impacted by the recall are the following: Middlefield Original Cheese Co-op 100% Grass-Fed Pepper Jack Cheese - eight-ounce packages, five-pound loaves, and 40-pound loaves - lot code: 251661 Copia Collective 100% Grass-Fed Pepper Jack Cheese - eight-ounce packages - lot code: 251661 Middlefield Original Cheese Co-op Horseradish Flavored Cheese - eight-ounce packages - lot code: 2524061 Middlefield Original Cheese Co-op Monterey Jack Cheese - eight-ounce packages and five-pound blocks with lot code: 251672 - 40-pound blocks with dates coded as 7-16-25B Farmers Cheese - eight-ounce packages and five-pound blocks with lot code: 251672 - 40-pound blocks with dates coded as 7-16-25B The products were produced on June 16, 2025, June 24, 2025, and July 16, 2025. They were shipped to manufacturers, distributors and retail stores in Ohio between July 14, 2025, and August 7, 2025, according to the FDA. The recall was initiated after testing conducted by the company revealed the presence of Listeria in the products. The company halted production while investigations were carried out, which revealed that the listeria came from environmental contamination that spread to food-contact areas. As of August 18, no illnesses had been reported in connection with the consumption of the recalled products. What People Are Saying Mary O'Riordan, a professor of microbiology and immunology at the University of Michigan Medical School, previously told Newsweek: "Listeria has an unusual capacity to grow at refrigerated temperatures. Although the bacterium can contaminate many types of food, cheeses or deli meats that are kept in cold storage for long periods in stores or at home are a place where listeria can keep growing. "Early symptoms of listeria infection look similar to other common foodborne infections, including fever, diarrhea and vomiting, so it's often not diagnosed right away. Unfortunately, sometimes listeria can spread into the brain and cause more serious illness, like meningitis. In those cases, if people experience headache, stiff neck or confusion, they should seek urgent medical attention." Haley F. Oliver, a professor of food science at Purdue University, previously told Newsweek: "Listeria monocytogenes is a common microorganism that can be found in the natural environment, for example, in soil. There are many factors that determine if someone gets listeriosis—a listeria infection. In most instances, an immunocompromised person—so young, old, pregnant or otherwise immunocompromised—must eat contaminated food. "The number of bacteria resulting in infection and the amount of time before illness varies considerably. Symptoms vary among people but can include fever, flu-like symptoms, headache, stiff neck, confusion and loss of balance." The FDA says on its website: "Pregnant women and their unborn or newborn baby, adults over the age of 65, and those with weakened immune systems, are all considered to be high-risk groups that are susceptible to the serious and adverse effects of listeriosis." What Happens Next The recall is ongoing, according to the FDA. Customers who purchased the recalled products should dispose of them or return them to their place of purchase for a refund.
Yahoo
an hour ago
- Yahoo
TransCelerate and FDA Collaborate to Advance Use of Pragmatic Elements in Clinical Trials
New Summary Report and Resource Guide Highlight Opportunities to Integrate Research into Routine Care and Enable Broader Trial Participation PHILADELPHIA, Aug. 19, 2025 /PRNewswire/ -- TransCelerate BioPharma (TransCelerate), a nonprofit organization dedicated to improving the health of people around the world by accelerating and simplifying clinical research, today announced the release of a summary report from a tabletop exercise conducted with the U.S. Food and Drug Administration's (FDA) CDER Center for Clinical Trial Innovation (C3TI), along with the newly published resource, Getting Started with Embedded Pragmatic Trials: A Resource Guide. Held in December 2024, the exercise convened more than 30 pharmaceutical R&D leaders from TransCelerate member companies and eight FDA offices to identify actionable opportunities to scale the use of pragmatic elements in clinical trials to enable more research to be conducted at the point of care. Pragmatic trials offer simplified designs, leverage routine care settings, and reach broader, more representative patient populations—making them well-suited to address public health challenges and areas of significant unmet clinical need. "Collaborative efforts like this help surface practical considerations for embedding clinical research into routine care," said Rob DiCicco, Vice President of Portfolio Management at TransCelerate. "It also highlights the value of FDA's Streamlined Trials Embedded in clinical Practice (STEP) initiative in supporting innovative trial designs that can improve patient access and generate reliable evidence from real-world care settings." TransCelerate's Embedded Pragmatic Trials initiative aims to accelerate the adoption of these trial designs by building awareness, engaging in productive dialogue with regulatory authorities and other stakeholders, and offering practical tools to guide implementation. "Pragmatic trials have the potential to transform how clinical research is conducted – bringing trials closer to where care is delivered and expanding patient access to clinical trials," said Kevin Bugin, Head of Global Regulatory Policy at Amgen and executive sponsor of TransCelerate's Embedded Pragmatic Trials initiative. "This exercise represents a critical step toward enabling this vision, and we are grateful for the FDA's partnership and engagement." As part of the informal, non-binding exercise, TransCelerate presented a hypothetical case study evaluating a new indication for a post-approval medication. The clinical trial design incorporated several pragmatic elements, including simplified data collection, broad eligibility criteria, and integration with electronic health records (EHRs). Key themes from the session include: Design and Oversight Considerations: The value of hybrid trial designs, fit-for-purpose investigator and third-party oversight frameworks, and early feasibility assessments to ensure data readiness and regulatory alignment. Data Integrity and Endpoint Alignment: Opportunities to improve data quality by integrating EHR data with thoughtful quality-by-design (QbD) approaches and clarified endpoint definitions. Value of Broad Agency Collaboration: The need for aligned expectations regarding endpoint selection, adjudication, blinding and inspection priorities across multiple FDA offices. Operational Efficiency and Privacy: Exploration of computational methods to ensure data integrity while preserving patient privacy during inspections. In parallel with the tabletop exercise, TransCelerate has released Getting Started with Embedded Pragmatic Trials: A Resource Guide, a robust tool designed to build understanding of embedded pragmatic trials and provide practical guidance for successful implementation. The guide identifies resources to help stakeholders navigate the design and implementation of trials that incorporate pragmatic elements such as simplified data collection, broad eligibility criteria, and EHR integration. Looking Ahead TransCelerate will continue to collaborate with global regulators, sponsors, and stakeholders to: Advance understanding and adoption of pragmatic trials through real-world case studies, tools, and shared learnings. Clarify operational distinctions between pragmatic and traditional trial models. Identify infrastructure-ready geographies to support implementation at scale. The full report, Enabling the Implementation of Pragmatic Elements at Scale: Summary Report from an FDA and TransCelerate Tabletop Exercise, is available here: To learn more about TransCelerate's Embedded Pragmatic Trials Initiative, visit: About TransCelerate BioPharma BioPharma (TransCelerate) is a nonprofit organization that fosters collaboration across the global biopharmaceutical research and development community to simplify clinical trials and help bring new treatments to patients faster, safer, and more efficiently. Headquartered in the Philadelphia area, TransCelerate has 20 member companies and a robust portfolio of initiatives focused on transforming connectivity, enabling information sharing and reuse, and driving innovative trial designs. For more information, please visit View original content to download multimedia: SOURCE TransCelerate BioPharma
CNBC
an hour ago
- CNBC
Eight Sleep CEO Matteo Franceschetti on sleep optimization, AI implementation and growth outlook
Matteo Franceschetti, Eight Sleep co-founder and CEO, joins 'Squawk Box' to discuss the implementing AI into its products, getting FDA approval to diagnose and mitigate sleep apnea, long-term growth outlook, and more.
